Trials / Active Not Recruiting
Active Not RecruitingNCT05718557
Study of PYX-106 in Solid Tumors
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Pyxis Oncology, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PYX-106 | Intravenous (IV) infusion |
Timeline
- Start date
- 2023-05-23
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2023-02-08
- Last updated
- 2025-08-03
Locations
20 sites across 3 countries: United States, Belgium, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05718557. Inclusion in this directory is not an endorsement.